Smith & Nephew plc: Q1 2025 Trading Update Summary
Business Context and Reporting Period
This Form 6-K filing reports the First Quarter 2025 trading update for Smith & Nephew plc, covering the period ended March 29, 2025. The company is a global medical technology business focused on Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The quarter comprised 62 trading days, one fewer than the comparable period in 2024.
Key Financial Metrics
- Revenue: Q1 2025 revenue was $1,407 million, compared to $1,386 million in Q1 2024.
- Growth Rates: Reported revenue growth was 1.6%. Underlying revenue growth (excluding currency and acquisition impacts) was 3.1%.
- Currency Impact: Foreign exchange headwinds reduced reported growth by 150 basis points (-1.5%).
- Profit Margins: The filing does not provide specific Q1 trading profit figures or margins. Full-year 2025 trading profit margin guidance is set between 19.0% and 20.0%.
- Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for cash flow, debt levels, or liquidity ratios for the quarter.
Material Changes vs. Prior Period
- Orthopaedics: Underlying revenue grew 3.2% (reported 1.8%). Growth was driven by US Hip and Knee Implants, Other Reconstruction, and Trauma & Extremities. Robotics consumables revenue reporting was reclassified to align with industry peers.
- Sports Medicine & ENT: Underlying revenue grew 2.4% (reported 0.9%). Strong performance in Established Markets was offset by headwinds in China.
- Advanced Wound Management: Underlying revenue grew 3.8% (reported 2.0%). Growth was driven by foams and Negative Pressure Wound Therapy (NPWT), partially offset by expected volatility in the SANTYL product line.
- Geography: Established Markets grew 4.1% underlying (US: 3.6%; Other Established: 5.0%). Emerging Markets declined 1.7% underlying, primarily due to China headwinds. Excluding China, Emerging Markets grew 14.7% underlying.
Guidance, Outlook, and Risks
- Full Year 2025 Guidance: Unchanged. Underlying revenue growth is expected to be around 5.0% (reported growth 5.4%). Trading profit margin is expected to expand to 19.0%–20.0%.
- Tariff Impact: Management expects a net tariff impact of $15 to $20 million in 2025 based on announced measures and mitigations. Over half of revenues are in the US, with two-thirds of US products manufactured in-market.
- China Headwinds: Management believes the peak impact of China's Volume-Based Procurement (VBP) has passed. Additional VBP headwinds in Arthroscopic Enabling Technologies are expected in the second half of 2025.
- Product Pipeline: Continued high cadence of launches, including the CATALYSTEM Hip System, LEGION Medial Stabilized inserts, and TESSA Spatial Surgery System (pending FDA clearance).
- Risks: Forward-looking statements are subject to risks including geopolitical conflicts, regulatory approvals, supply chain disruptions, and foreign exchange volatility.
Investor Verification Checklist
- Verify the specific Q1 trading profit margin and cash flow figures in the upcoming Half-Year results (scheduled for August 5, 2025), as they are not detailed in this trading update.
- Monitor the timeline and impact of the expected Volume-Based Procurement (VBP) extension in China for Arthroscopic Enabling Technologies in H2 2025.
- Track the actual financial impact of tariffs against the $15–$20 million estimate provided by management.
- Confirm the FDA clearance status for the TESSA Spatial Surgery System and its potential contribution to the Sports Medicine portfolio.
- Review the reclassification of robotics consumables revenue to ensure accurate year-over-year comparisons for the Orthopaedics segment.